Why Are Women More Likely Than Men to Suffer Hair Loss From Taxotere®?

Women are more likely than men to suffer hair loss from Taxotere® simply because they’re more likely to be diagnosed with breast cancer. Taxotere (docetaxel) is a popular chemotherapy treatment for this disease. Hair loss, also known as alopecia, is a common side effect of chemotherapy. Most patients can expect their hair to grow back within a few months of ending their treatment.

However, recent studies link Taxotere to permanent hair loss. Some patients have even filed lawsuits against the drug’s manufacturer, Sanofi-Aventis, alleging that the pharmaceutical company sold the drug without properly testing it, and failed to disclose the associated dangers and risks.

According to the non-profit organization Breastcancer.org, as many as 250,000 new cases of invasive breast cancer are diagnosed annually in the United States. Women make up the vast majority of those cases, while fewer than 2,500 men are diagnosed with breast cancer each year. Additionally, women in the United States have an approximately 1 in 8 lifetime risk of developing breast cancer, while the lifetime risk for men is 1 in 1,000.

Taxotere is the most prescribed drug in its class. As many as 75 percent of breast cancer patients are prescribed Taxotere, meaning that millions of women may be at risk of developing devastating permanent alopecia.

Did You Suffer Permanent Hair Loss?

If you’ve suffered permanent hair loss after being prescribed Taxotere, and weren’t informed that long-term alopecia could be a side effect of your chemotherapy treatment, you may be able to file a personal injury lawsuit to seek compensation for damages, such as pain and suffering, and loss of quality of life. McGartland Law Firm can help you explore your legal options. Call our law office at 1-866-832-9300 or fill out our online contact form to schedule a free initial consultation to discuss your case.